Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.10.1126/science.3798106 Search in Google Scholar

2. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.10.1056/NEJMoa052122 Search in Google Scholar

3. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36.10.1016/S0140-6736(07)60028-2 Search in Google Scholar

4. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneli V, et al. Trastuzumab containing regiments for early breast cancer. Cochrane Database Syst Rev 2012; 4: CD006243.10.1002/14651858.CD006243.pub2671821022513938 Search in Google Scholar

5. Matos E. [Treatment of HER2 positive breast cancer patients]. [Slovenian]. Zdrav Vestn 2012; 81: 236-45. Search in Google Scholar

6. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer Jr CE et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366-73.10.1200/JCO.2011.35.0868316424221768458 Search in Google Scholar

7. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Rolski J, et al. Phase III Randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC -> T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC -> TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 Study. [Abstract]. Cancer Res 2009; 69: 500S.10.1158/0008-5472.SABCS-09-62 Search in Google Scholar

8. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-20.10.1056/NEJMoa05302816495393 Search in Google Scholar

9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.10.1056/NEJM20010315344110111248153 Search in Google Scholar

10. National Comprehensive Cancer network. NCCN guidelines. Avaiable 10th March, 2013: http://www.nccn.org/index.asp Search in Google Scholar

11. Caussa L, Kirova YM, Gault N, Pierga JY, Savignoni A, Campana F, et al. The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study. Eur J Cancer 2011; 47: 65-73.10.1016/j.ejca.2010.08.01320843680 Search in Google Scholar

12. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Traastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer. N Engl J Med 2005; 353: 1659-72.10.1056/NEJMoa05230616236737 Search in Google Scholar

13. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973; 32: 302-14.10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2 Search in Google Scholar

14. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat Rev C ardiol 2010; 7: 564-75.10.1038/nrcardio.2010.121 Search in Google Scholar

15. Chien AJ, Rugo HS. The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf 2010; 9: 335-46.10.1517/14740331003627441 Search in Google Scholar

16. Ewer MS, Tan-Chiu E. Reversibility of trastuzumab cardiotoxicity: is the concept alive and well? J Clin Oncol 2007; 25: 5532-3. Author reply: 5533-4.10.1200/JCO.2007.14.0657 Search in Google Scholar

17. Steinherz LJ, Steihherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4-20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-7.10.1001/jama.1991.03470120074036 Search in Google Scholar

18. Klein PM, Dybdal N. Trastuzumab and cardiac dysfunction: update on preclinical studies. Semin Oncol 2003; 30(5 Suppl 16): 49-53.10.1053/j.seminoncol.2003.08.007 Search in Google Scholar

19. Schneider JW, Chang AY, Rocco TP. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin Oncol 2001; 28(5 Suppl 16): 18-26.10.1053/sonc.2001.28546 Search in Google Scholar

20. Koželj M, Zver S, Zadnik V. Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoetic stem cell transplantation. Radiol Oncol 2013; 47: 161-5.10.2478/raon-2013-0019 Search in Google Scholar

21. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin s disease. JAMA 1993; 270: 1949-55.10.1001/jama.1993.03510160067031 Search in Google Scholar

22. Schultz-Hector S. Radiation-induced heart disease: review of experimental data on dose response and pathogenesis. Int J Radiat Biol 1992; 61: 149-60.10.1080/09553009214550761 Search in Google Scholar

23. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366: 2087-106.10.1016/S0140-6736(05)67887-7 Search in Google Scholar

24. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 2000; 355: 1757-70. Search in Google Scholar

25. Kovac V, Smrdel U. Meta-analyses of clinical trials in patients with non-small cell lung cancer. Minireview. Neoplasma 2004; 51: 334-40. Search in Google Scholar

26. Darby SC, McGale P, Taylor CW, Peto R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries. Lancet Oncol 2005; 6: 557-65.10.1016/S1470-2045(05)70251-5 Search in Google Scholar

27. Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Monoclonal antibody to HER-2/neu receptor modulates repair of radiation- induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999; 59: 1347-55. Search in Google Scholar

28. Law AB, Evans T, Hayward RL, Higgins GS, Murray KL, Summers D, et al. Possible radiation sensitisation by trastuzumab leading to radiation-induced myelitis. Breast Care (Basel) 2009; 4: 40-2.10.1159/000193069294201020877683 Search in Google Scholar

29. Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009; 27: 2638-44.10.1200/JCO.2008.17.9549269039019349549 Search in Google Scholar

30. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006; 24: 4107.10.1200/JCO.2005.04.955116908934 Search in Google Scholar

31. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, et al. Assessement of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamyde followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005; 23: 7811-19.10.1200/JCO.2005.02.409116258083 Search in Google Scholar

32. Shaffer R, Tyldesley S, Rolles M, Chia S, Mohamed I. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol 2009; 90: 122-6.10.1016/j.radonc.2008.09.00318976826 Search in Google Scholar

33. Carver JR. Management of trastuzumab-related cardiac dysfunction. Prog Cardiovasc Dis 2010; 53: 130-9.10.1016/j.pcad.2010.07.00120728700 Search in Google Scholar

34. Goel S, Simes RJ, Beith JM. Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer. Asia Pac J Clin Oncol 2011; 7: 276-80.10.1111/j.1743-7563.2011.01422.x21884439 Search in Google Scholar

35. Fiuza M. Cardiotoxicitiy associated with trastuzumabTreatment of HER2+ breast cancer. Adv Ther 2009: 26(Suppl 1): S9- 17.10.1007/s12325-009-0048-z19669637 Search in Google Scholar

36. Wondergem J, Strootman EG, Frölich M, Leer JWH, Noordijk EM. Circulating atrial natriuretic peptide plasma levels as a marker for cardiac damage after radiotherapy. Radiother Oncol 2001; 58: 295-301.10.1016/S0167-8140(00)00303-0 Search in Google Scholar

37. Geiger S, Lang V, Suhl P, Heinemann V, Stemmler HJ. Anticancer therapy induced cardiotoxicity: review of the literature. Anticancer Drugs 2010, 21: 578-90.10.1097/CAD.0b013e3283394624 Search in Google Scholar

38. Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, et al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 2011; 148: 194-8.10.1016/j.ijcard.2009.09.564 Search in Google Scholar

39. Zeglinski M, Ludke A, Jassal DS, Singal PK. Trastuzumab-induced cardiac dysfunction: a ‘dual-hit’. Exp Clin Cardiol 2011; 16: 70-4. Search in Google Scholar

40. Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol 2006; 33: 2-14.10.1053/j.seminoncol.2005.11.001 Search in Google Scholar

41. Antman EM. Decision making with cardiac troponin tests. N Engl J Med 2002; 346: 2079-82.10.1056/NEJMe020049 Search in Google Scholar

42. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and progonostic implications of troponin I evaluation. J Clin Oncol 2010; 28: 3910-6.10.1200/JCO.2009.27.3615 Search in Google Scholar

43. Seino Y, Ogawa A. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 2004; 6: 295-300.10.1016/j.ejheart.2003.12.009 Search in Google Scholar

44. Sengupta PP, Northfelt DW, Gentile F, Zamorano JL, Khandheria BK. Trastuzumab-induced cardiotoxicity: Heart failure at the crossroads. Mayo Clin Proc 2008; 83: 197-203.10.1016/S0025-6196(11)60840-9 Search in Google Scholar

45. Gianizzi P, Temporelli PL, Bosimini E, Silva P, Imparato A, Corra U, et al. Independent and incremental prognostic value of Doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. J Am Coll Cardiol 1996; 28: 383-90. 10.1016/S0735-1097(96)00163-5 Search in Google Scholar

46. Suzuki J, Yanagisawa A, Shigejama T, Tsubota J, Yasumura T, Shimoyama K, et al. Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography. Angiology 1999; 50: 37-45.10.1177/0003319799050001059924887 Search in Google Scholar

47. Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo- Riedinger A, et al. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer. Breast Cancer Res Treat 2011; 130: 845-54.10.1007/s10549-011-1714-9 Search in Google Scholar

48. Gulati VK, Katz WE, Follansbee WP, Gorcsan J. Mitral annular descent velocity by tissue Doppler echocardiography as an index of global left ventricular function. Am J Cardiol 1996; 77: 979-84.10.1016/S0002-9149(96)00033-1 Search in Google Scholar

49. Benvenuto GM, Ometto R, Fontanelli A, Fortunato A, Ruffini PA, Fosser V, et al. Chemotherapy related cardiotoxicity: new diagnostic and preventive strategies. Ital Heart J 2003; 4: 655-67. Search in Google Scholar

50. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-20210.1001/jama.289.2.19412517230 Search in Google Scholar

51. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992; 327: 685-91. Search in Google Scholar